The new team members will bring a greater diversity of perspectives, interdisciplinary skills, and international experience to MIG Capital. With the four new employees, the team now consists of 11 people. Fei Tian, a doctor with a doctorate, has joined the Life Sciences team as a Principal, while Frederick Michna, a business economist, and Oliver Kahl, a physicist with a doctorate, have joined the Deeptech team. Andreas Kastenbauer, a business economist, is a new Partner at MIG Capital and will be part of the Life Sciences team.
MIG Capital: “We can now assess young, disruptive business models even better from a variety of perspectives.”
Michael Motschmann, Founder and Managing Partner of MIG Capital, says:
"With this significant expansion of our team, we are addressing new technological and strategic challenges in selecting new investment opportunities and supporting our portfolio of currently 32 portfolio companies through to exit. Furthermore, with the new, younger members, we have succeeded in creating a good generational mix and, at the same time, achieving an even more professional approach to convergence. Thanks to our team of experts, we can now assess young, disruptive business models even better from a wide variety of perspectives."
The investor’s active portfolio includes the Munich-based companies AMSilk, Efficient Energy, Immatics, Iomx, IQM, Isarna Therapeutics, Kewazo, Konux, Navvis, Temedica and WealthpilotThe Munich-based investor had been investing in Biontech since 2008 and completed the exit in 2021.
